CNS Safety & Seizure Liability Assessment
Prediction of drug-induced neurotoxicity and seizure risk
PreclinicalActive
Key Facts
Indication
Prediction of drug-induced neurotoxicity and seizure risk
Phase
Preclinical
Status
Active
Company
About 28Bio
28Bio is a private, preclinical-stage biotech leveraging its proprietary Nexon™ platform to create engineered human brain and peripheral nervous system organoids for neurotoxicity and efficacy testing. The company's technology, which combines 3D tissue engineering, embedded neural electrodes, and AI-driven analysis, has demonstrated superior predictive performance compared to animal models, as evidenced by its retrospective Endurance Study. 28Bio operates primarily as a platform and services company, offering predictive assays to pharmaceutical partners to de-risk neurological drug development, and is currently in a pre-revenue stage.
View full company profile